

NAME OF TRIAL	Research Ethics No (REC)	Target no of Patients	Recruitment Deadline	Trial Status	Did the trial Recruit to Target?
A long term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA containing regimens for chronic hepatitis C infection (CHC)	11/LO/0278	6	30/09/2012	Open	Still Open
A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMPARED WITH RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY GA101	11/NW/0298	6	30/06/2013	Open	Still Open
A Multi-Centre 3-Year Follow-Up study to Assess the Durability of Sustained Virologic Resonse in Alisporivir-Treated Chronic Hepatitis C Patients	12/SC/0185	1	23/03/2015	Open	Still Open
A new vaccine against meningitis groupB: A second follow on study	12/SC/0384	10	01/07/2013	Open	Still Open
A Phase 3 Evaluation of Daclatasvir in Combination with Peg-interferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis C Genotype 1b who are Treatment Naïve or Prior Relapsers to Alfa/RBV Therapy	13/LO/0206	4	26/09/2013	Open	Still Open
A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naïve Subjects with Chronic Hepatitis C Genotype 1b Infection	12/LO/0827	5	20/03/2014	Open	Still Open
A Phase 3, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Participants with Moderately to Severely Active Crohn's Disease	11/SC/0327	5	15/09/2013	Open	Still Open
A Phase 3, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease	11/SC/0329	5	15/09/2013	Open	Still Open
A phase III open-label randomised study, to evaluate the immunogenicity and safety of the concomitant administration of V419 (PR5I) given at 2, 3 and 4 months of age with two types of meningococcal serogroup C conjugate (MCC) vaccines given at 3 and 4 months of age, and followed by the administration at 12 months of age of a combined Haemophilus influenzae type b-MCC vaccine.	11/SW/0328	30	31/08/2012	Open	Still Open
A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon.	12/LO/1590	5	07/05/2013	Open	Still Open
A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLEDSTUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA	12/LO/1876	No date agreed with Sponsor	6	Open	Still Open
A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-? (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN / RBV treatment	11/SC/0177	1	31/08/2013	Open	Still Open
A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer?) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison with Intravenous Iron Sucrose in Subjects with Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).	11/NE/0124	10	31/07/2013	Open	Still Open
A Phase II Study of Dasatinib Therapy in Children and Adolescents with Ph+ Leukemia with Resistance of Inolerance to Imatinib Phase I/II study of Scr/ABi tyrosine kinase inhibitor dasatinib (BMS-354825) in children and adolescents with relapsed or refractory leukemia	09/H0405/51	4	15/04/2015	Open	Still Open
A Proof of Concept Study for GSK249320 versus placebo in Stroke Patients	11/LO/1447	8	31/10/2014	Open	Still Open
A Randomised, Double Blind, Parallel Group, Multicentre Phase IIb study to complare ticagrelor with clopidogrel treatment on the risk of cardiovascular deat, myocardial infarction and ischeamic stroke in patients with established Peripheral Artery Disease	12/EM/0395	20	14/06/2014	Open	Still Open
A randomized, controlled, open-label, parallel-group, multi-center study to compare the effect of Intrathecal Baclofen Therapy (ITB Therapy?) versus Best Medical Treatment (BMT) on severe spasticity in post-stroke patients after 6 months active treatment	10/H0803/96	4	31/03/2011	Open	Still Open

A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer	11/LO/0608	5	12/07/2012	Open	Still Open
A study exploring the efficacy and safety of once-daily oral Rivaroxaban (BAY 59-7939) compared with that of dose-adjusted oral vitamin K antagonist (VKA) for the prevention of cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion	12/LO/1285	12	28/09/2013	Open	Still Open
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group	08/H0311/120	30	01/06/2013	Open	Still Open
BIA-2093-311: Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as monotherapy for patients with newly diagnosed partial-onset seizures: A double-blind, randomized, active-controlled, parallel-group, multicenter clinical study	10/H0903/29	6	01/12/2013	Open	Still Open
Clinical Protocol AI444026: An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and MBS-790052 With or Without BMS-650032 for subjects with Chronic Hepatitis C	11/SC/0358	4	30/09/2015	Open	Still Open
OVATION POST-MARKET STUDY Ovation Abdominal Stent Graft System	11/LO/0922	15	No date agreed with Sponsor	Open	Still Open
Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active Rheumatoid Arthritis (RA) who have demonstrated an inadequate response to prior disease-modifying anti-rheumatic drugs (DMARDs) treatment and have initiated RoActemra® (Tocilizumab, TCZ) in combination with MTX.	12/EE/0176	5	31/12/2013	Open	Still Open
Surgical replacement and transcatheter aortic valve implantation	12/LO/0491	25	31/10/2018	Open	Still Open
Zenith TX2 Low-Profile TAA Endovascular Graft Clinical Study #08-017-03	10/H0808/27	10	30/09/2010	Open	Still Open
A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Tnerferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Chronic Hepatitis C Genotypes 1 and 4	12/SC/0031	2	30/04/2014	Open	N/A
A Phase 3, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group study of the Efficacy and Safety of Lenalidomide (Revlimid?) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukaemia following Second-line Therapy.	09/H0301/5	5	30/11/2013	Open	N/A
A Phase II single blind, randomized, placebo controlled trial to study the efficacy and safety of anti-von Willebrand factor Nanobody administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.	10/H0709/60	3	31/05/2012	Open	N/A
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant	10/H0406/16	5	30/06/2013	Open	N/A
A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-? and ribavirin in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment	11/SC/0176	5	No date agreed with Sponsor	Open	N/A
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa?) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma	12/LO/1076	5	31/05/2015	Open	N/A
An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1-positive unresectable and progressive metastatic cutaneous melanoma.	10/H0806/106	4	30/12/2011	Open	N/A
A multi-centre double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta	11/H0707/6	6	No date agreed with Sponsor	Withdrawn	N/A
Comparison of New Ostomy Barriers and Drainable Pouches to currently Marketed Ostomy Pouching Systems	12/EE/0078	10	No date agreed with Sponsor	Withdrawn	N/A
European Study of POBA versus Cotavance Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia	11/LO/0256	15	28/02/2013	Withdrawn	N/A
Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)	13/LO/0425	5	31/05/2013	Closed - In Follow Up	Yes
study to assess the incidence of mutations in the tyrosine kinase domain of the epidermal growth factor receptor in UK patients with newly diagnosed locally advanced or metastatic non-small cell lung cancer and to investigate the quality of life of these patients undergoing first-line monotherapy with erlotinib (Tarceva®).	10/H0713/75	10	No date agreed with Sponsor	Closed - In Follow Up	Yes

A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis.	09/H0720/135	4	14/10/2011	Closed - In Follow Up	Yes
A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis.	10/H1307/8	4	14/10/2011	Closed - In Follow Up	Yes
A Phase 3, randomised, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects.	10/H0713/76	2	30/04/2011	Closed - In Follow Up	Yes
A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency	09/H1306/82	2	31/12/2012	Closed - In Follow Up	Yes
A phase III, open-label, multicentre study to evaluate the immunogenicity, safety and reactogenicity of revaccination dose of the GlaxoSmithKline Biologicals' quadrivalent seasonal influenza candidate vaccine GSK2321138A, administered to children who previously participated in study 115345 (FLU D-QIV-004 PRI)	12/SW/0237	9	05/07/2013	Closed - In Follow Up	Yes
A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON-PERMANENT ATRIAL FIBRILLATION	12/LO/0009	6	No date agreed with Sponsor	Closed - In Follow Up	Yes
An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Who Have Completed Studies C-1801, C-1802 and a Dosing Suspension Safety Evaluation (STRATA)	06/Q0505/31		No date agreed with Sponsor	Closed - In Follow Up	Yes
Efficacy Study of a Quadrivalent Influenza Vaccine in Children (FLU D-QIV)	11/SC/0313	25	14/12/2011	Closed - In Follow Up	Yes
Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms	11/EE/0219	5	No date agreed with Sponsor	Closed - In Follow Up	Yes
Protocol RTA115450: A two part double blind, randomised, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric patients with previously treated chronic immune (idopathic) thrombocytopenic purpura (ITP)	12/NW/0134	2	No date agreed with Sponsor	Closed - In Follow Up	Yes
To prospectively collect global 'real world' safety and clinical performance data on Endurant Stent Graft System. This is a registry only.	09/H0308/124	10	No date agreed with Sponsor	Closed - In Follow Up	Yes
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of MAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma.	10/H0903/39	3	31/08/2016	Closed - In Follow Up	No
A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER (MAINSAIL)	09/H0720/132	15	No date agreed with Sponsor	Closed - In Follow Up	No
A Phase 3, Multicentre, Randomised, Open-Label, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukaemia. (The Origin Trial)	09/H1107/103	5	31/05/2011	Closed - In Follow Up	No
A Phase 3, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Participapnts with Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy	11/SC/0326	5	15/09/2013	Closed - In Follow Up	No
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS 9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults. (GS-US-216-0114)	10/H0711/34	8	04/06/2010	Closed - In Follow Up	No
A Phase III Prospective, Two-cohort, Non-randomized, Multi-centre, Multi-national, Open Label Study to Assess the Safety of Assisted- and Self-administered Subcutaneous Trastuzumab as Adjuvant Therapy in Patients with Operable HER2-positive Early Breast Cancer	12/SC/0139	6	No date agreed with Sponsor	Closed - In Follow Up	No
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PERTUZUMAB + TRASTUZUMAB + DOCETAXEL vs. PLACEBO + TRASTUZUMAB + DOCETAXEL IN PREVIOUSLY UNTREATED HER2-POSITIVE METASTATIC BREAST CANCER	08/H0606/29	5	30/09/2012	Closed - In Follow Up	No
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer.	09/H0402/92	10	No date agreed with Sponsor	Closed - In Follow Up	No

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma	10/H0806/71	No date agreed with 5 Sponsor	Closed - In Follow Up	No
A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma	11/SC/0479	4 30/11/2012	Closed - In Follow Up	No
An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older with Partial Onset Seizures	11/NE/0039	5 30/11/2012	Closed - In Follow Up	No
An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of antiangiogenic (VEGF-targeted and mTOR inhibitor) therapies (GOLD)	11/LO/0548	4 31/10/2012	Closed - In Follow Up	No
CIS Study: An international, Multi-centre, Randomised, Double-Blind, placebo controlled parallel group study to evaluate the efficacy and safety of two year treatment with Teriflunomide 7mg once daily and 14mg once daily versus the placebo in patients with a first clinical episode suggestive of multiple sclerosis	07/H0707/112	No date agreed with 7 Sponsor	Closed - In Follow Up	No
CoreValve Advance International Post Market Study A Multi-centre, Interventional, Prospective, Post-Market Release Study	10/H0724/33	No date agreed with 100 Sponsor	Closed - In Follow Up	No
Phase II randomised, placebo controlled trial to investigate repeat dose antimicrobial photodynamic therapy in patients with chronic venous leg ulcers	08/H0206/68	No date agreed with 5 Sponsor	Closed - In Follow Up	No
TEMPO Extension: Long-term extension study of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14mg) in patients with multiple sclerosis with relapses.	06/MRE04/84	No date agreed with 10 Sponsor	Closed - In Follow Up	No
A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral Therapy-Experienced Adults.- ING111762	10/H0706/67	1 07/05/2015	Closed - Follow Up Complete	Yes
A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimuscarinics and Dissatisfied due to Lack of Efficacy	12/LO/0410	6 30/11/2012	Closed - Follow Up Complete	No
A multicentre, single arm study of Trastuzumab Emtasine (TDM-1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti-HER2 and chemotherapy-based treatment.	12/LO/1351	5 30/09/2013	Closed - Follow Up Complete	No
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain	10/H1107/42	6 31/08/2012	Closed - Follow Up Complete	No
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b Versus Warfarin In Subjects with Atrial Fibrillation – Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE – AF TIMI - 48)	09/H0706/8	10 18/05/2012	Closed - Follow Up Complete	No
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (=16 To 80 Years Old) With Partial Onset Seizures	11/NE/0038	5 02/05/2012	Closed - Follow Up Complete	No
A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis	10/H0904/49	No date agreed with 8 Sponsor	Closed - Follow Up Complete	No
ALTITUDE: A randomised, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality	07/H0606/126	10 01/01/2012	Closed - Follow Up Complete	No
FINISH 3: A Phase 3, Randomised, Single Blind, Controlled Trial of Topical Fibrocaps in Intraoperative Surgical Hemostasis	12/NE/0181	10 31/03/2013	Closed - Follow Up Complete	No
GWCA0962: A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy	10/MRE00/66	25 31/12/2013	Closed - Follow Up Complete	No
A Clinical Evaluation of ST Changes in a Group of Patients having Ventricular Arrhythmias	12/WS/0285	20 30/04/2016	In set up	N/A
A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	13/LO/0129	6 31/05/2014	In set up	N/A

A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1b chronic hepatitis C infection	13/LO/0268	2	23/11/2016	In set up	N/A
B1971009 Phase 3 study to assess Meningococcal B Vaccine	11/YH/0379	50	Sponsor	In set up	N/A